Overview
McDermott Will & Emery has advised ANTABIO, a clinical stage biopharmaceutical company developing novel treatments for severe drug-resistant bacterial infections, on its Series B financing.
Investors include the AMR Action Fund and the European Innovation Council (EIC) Fund.
The financing will be used to support the clinical development of MEM-ANT3310, a next generation antibacterial combination currently in phase 1 trials.
The McDermott team that advised Antabio comprised: *
- Anthony Paronneau, partner, Natacha Vasak and Alice Villagrasa, associates
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
